Drug Profile


Alternative Names: Deuteporphyrin; DTBF

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  • Class Antineoplastics
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma
  • Phase I/II Bladder cancer

Most Recent Events

  • 07 Oct 2016 (Company) completes a phase I/II trial in Bladded cancer in China (ChiCTR-ONC14004366)
  • 01 Oct 2016 Phase-II clinical trials in Cholangiocarcinoma (Inoperable/Unresectable, Late-stage disease) in China (IV) (NCT02955771)
  • 30 Apr 2012 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical completes a phase I trial in Cancer in China (NCT01481597)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top